Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults

• Published in: Vaccine 2000-03, Vol.18 (17), p.1763-1772
• Main Authors: Gonzalez, Idalia M, Karron, Ruth A, Eichelberger, Maryna, Walsh, Edward E, Delagarza, Vincent W, Bennett, Richard, Chanock, Robert M, Murphy, Brian R, Clements-Mann, Mary Lou, Falsey, Ann R
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Adults; Aged; Aged, 80 and over; Antibodies, Viral - blood; Antibody Formation - drug effects; Antibody Formation - immunology; Biological and medical sciences; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Elderly; Epidemiology. Vaccinations; Female; Fundamental and applied biological sciences. Psychology; General aspects; HN Protein; Humans; Immunity, Mucosal - drug effects; Immunity, Mucosal - immunology; Immunoglobulin A - blood; Immunoglobulin G - blood; Infectious diseases; Male; Medical sciences; Microbiology; Middle Aged; Nasal Mucosa - immunology; Nasal Mucosa - virology; Regression Analysis; respiratory syncytial virus; Respiratory syncytial virus vaccines; Respiratory Syncytial Virus, Human - immunology; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies; Vaccines, Attenuated - administration & dosage; Vaccines, Attenuated - adverse effects; Vaccines, Attenuated - immunology; Viral Envelope Proteins - administration & dosage; Viral Envelope Proteins - adverse effects; Viral Envelope Proteins - immunology; Viral Proteins - administration & dosage; Viral Proteins - adverse effects; Viral Proteins - immunology; Viral Vaccines - administration & dosage; Viral Vaccines - adverse effects; Viral Vaccines - immunology; Virology
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/S0264-410X(99)00527-7

The safety and immunogenicity of the live attenuated cold-passaged, temperature-sensitive ( cpts) 248/404 respiratory syncytial virus (RSV) A2 and the RSV A2 purified F glycoprotein (PFP-2) vaccine candidates were evaluated in a placebo-controlled trial in 60 healthy young adults and 60 healthy elderly subjects using simultaneous and sequential ( cpts 248/404 followed by PFP-2) vaccination schedules. Both vaccines were well tolerated. The cpts 248/404 vaccine was moderately infectious in both young and old volunteers, but was highly restricted in replication in those who were infected. After both vaccines, RSV neutralizing antibody (neut Ab) titers increased fourfold in 22% of young subjects and in 16% of elderly subjects. Of those with low levels of RSV neut Ab (titer